Phase 3 Trial of Navenibart for Hereditary Angioedema Initiated by Astria Therapeutics
Astria Therapeutics has initiated Phase 3 trial for navenibart in patients with hereditary angioedema.
Company
Pharmaceutical intelligence for Astria Therapeutics with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.